Drug details
Abilify Asimtufii (aripiprazole for extended-release injectable suspension)
type of Antipsychotics, Second Generation, Antimanic Agents
Abilify Asimtufii (aripiprazole) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and as maintenance monotherapy treatment of bipolar I disorder in adults.
The drug is often used to treat Schizophrenia .
This drug may have the following side effects:
- vomiting,
- diarrhea,
- dizziness,
- weight gain,
- restlessness/inability to sit still,
- injection site pain,
- sedation,
- constipation,
- dry mouth,
- abdominal discomfort,
- upper respiratory tract infection,
- joint pain,
- back pain,
- muscle aches,
- musculoskeletal pain,
- tremor, and
- nasal congestion.
The following drugs are related to Abilify Asimtufii, either as a replacement or used together:
- Abilify (aripiprazole)
- Abilify Maintena (aripiprazole extended-release injectable suspension)
- Abilify MyCite (aripiprazole tablets with sensor)
- Vraylar (cariprazine capsules)
- Eskalith (lithium carbonate)
- Geodon (ziprasidone)
- Lamictal (lamotrigine)
- Lamictal XR (lamotrigine extended-release tablets)
- Latuda (lurasidone hcl tablets for oral administration)
- Lybalvi (olanzapine and samidorphan tablets)
- Zyprexa (olanzapine)
- Zyprexa Relprevv (olanzapine extended release injectable suspension)
- Risperdal (risperidone)
- Risperdal Consta (risperidone)
- Uzedy (risperidone)